NCT01338012 - Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Prostate Cancer

Interventions

BIOLOGICAL

sipuleucel-T

Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).

Trial Locations (4)

92653

Orange County Urology Associates, Laguna Hills

97239

Oregon Health & Science University, Portland

98101

Virginia Mason Hospital, Seattle

Virginia Mason Medical Center, Seattle